Pure Global
NCT06246110

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Eikon Therapeutics·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
EIK1001
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Eikon Therapeutics
Location
Baltimore,White Plains, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Feb 06, 2024
End date
Dec 01, 2027
Enrollment
70 participants
Primary outcome

Percentage of participants with safety event during treatment

Summary

This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who
 have not received any treatment through the vein for the advanced disease.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06246110
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06246110 through Pure Global AI's free database. This Phase 2 trial is sponsored by Eikon Therapeutics and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.